IN2014MN01755A - - Google Patents
Info
- Publication number
- IN2014MN01755A IN2014MN01755A IN1755MUN2014A IN2014MN01755A IN 2014MN01755 A IN2014MN01755 A IN 2014MN01755A IN 1755MUN2014 A IN1755MUN2014 A IN 1755MUN2014A IN 2014MN01755 A IN2014MN01755 A IN 2014MN01755A
- Authority
- IN
- India
- Prior art keywords
- compounds
- formula
- present disclosure
- heteroaryl
- pharmaceutically acceptable
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 1
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Radiology & Medical Imaging (AREA)
- Pathology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Psychiatry (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
Abstract
The present disclosure is related to heteroaryl compounds as MEK inhibitors. These compounds include heteroaryl compounds of Formula (I) their pharmaceutically acceptable salts combinations with suitable medicament and pharmaceutical compositions thereof. The present disclosure also includes processes of preparation of the compounds and their use in methods of treatment. The compounds as disclosed herein are of Formula (I) below:
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN1755MUN2014 IN2014MN01755A (en) | 2012-03-14 | 2013-03-11 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN288KO2012 | 2012-03-14 | ||
| IN1755MUN2014 IN2014MN01755A (en) | 2012-03-14 | 2013-03-11 | |
| PCT/IB2013/051908 WO2013136249A1 (en) | 2012-03-14 | 2013-03-11 | Heterocyclyl compounds as mek inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014MN01755A true IN2014MN01755A (en) | 2015-07-03 |
Family
ID=47997632
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN1754MUN2014 IN2014MN01754A (en) | 2012-03-14 | 2013-03-11 | |
| IN1755MUN2014 IN2014MN01755A (en) | 2012-03-14 | 2013-03-11 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN1754MUN2014 IN2014MN01754A (en) | 2012-03-14 | 2013-03-11 |
Country Status (35)
| Country | Link |
|---|---|
| US (5) | US9428499B2 (en) |
| EP (2) | EP2834236B1 (en) |
| JP (3) | JP6093384B2 (en) |
| KR (4) | KR102241111B1 (en) |
| CN (4) | CN108383836B (en) |
| AP (2) | AP3859A (en) |
| AU (4) | AU2013234009B2 (en) |
| BR (1) | BR112014022713B1 (en) |
| CA (2) | CA2865167C (en) |
| CL (2) | CL2014002412A1 (en) |
| CO (2) | CO7160029A2 (en) |
| CR (2) | CR20140464A (en) |
| CU (2) | CU24335B1 (en) |
| DK (2) | DK2834236T3 (en) |
| DO (2) | DOP2014000204A (en) |
| EA (2) | EA029768B1 (en) |
| ES (2) | ES2741896T3 (en) |
| GE (2) | GEP201706774B (en) |
| GT (2) | GT201400195A (en) |
| IL (2) | IL234559A (en) |
| IN (2) | IN2014MN01754A (en) |
| MA (2) | MA37405A1 (en) |
| MX (3) | MX355474B (en) |
| MY (2) | MY174188A (en) |
| NI (2) | NI201400107A (en) |
| NZ (2) | NZ629432A (en) |
| PE (2) | PE20141974A1 (en) |
| PH (2) | PH12014502040B1 (en) |
| PL (1) | PL2834237T3 (en) |
| SG (2) | SG11201405006PA (en) |
| TN (2) | TN2014000357A1 (en) |
| TR (1) | TR201811976T4 (en) |
| UA (2) | UA114907C2 (en) |
| WO (2) | WO2013136254A1 (en) |
| ZA (1) | ZA201406186B (en) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8754114B2 (en) | 2010-12-22 | 2014-06-17 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 |
| NZ629432A (en) | 2012-03-14 | 2017-01-27 | Lupin Ltd | Heterocyclyl compounds as mek inhibitors |
| RS58514B1 (en) | 2012-06-13 | 2019-04-30 | Incyte Holdings Corp | Substituted tricyclic compounds as fgfr inhibitors |
| US9388185B2 (en) | 2012-08-10 | 2016-07-12 | Incyte Holdings Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
| US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
| PH12015502383B1 (en) | 2013-04-19 | 2023-02-03 | Incyte Holdings Corp | Bicyclic heterocycles as fgfr inhibitors |
| JP6403172B2 (en) * | 2013-10-25 | 2018-10-10 | シャンハイ ヘンルイ ファーマスーティカル カンパニー リミテッドＳｈａｎｇｈａｉ Ｈｅｎｇｒｕｉ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． | Ketone derivatives of pyridine, processes for their preparation, and their pharmaceutical applications |
| WO2016009306A1 (en) * | 2014-07-15 | 2016-01-21 | Lupin Limited | Heterocyclyl compounds as mek inhibitors |
| WO2016035008A1 (en) * | 2014-09-04 | 2016-03-10 | Lupin Limited | Pyridopyrimidine derivatives as mek inhibitors |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| TWI712601B (en) | 2015-02-20 | 2020-12-11 | 美商英塞特公司 | Bicyclic heterocycles as fgfr inhibitors |
| MA41551A (en) | 2015-02-20 | 2017-12-26 | Incyte Corp | BICYCLIC HETEROCYCLES USED AS FGFR4 INHIBITORS |
| US9580423B2 (en) | 2015-02-20 | 2017-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| EP3558979B1 (en) | 2016-12-22 | 2021-02-17 | Boehringer Ingelheim International GmbH | Novel benzylamino substituted quinazolines and derivatives as sos1 inhibitors |
| AR111960A1 (en) | 2017-05-26 | 2019-09-04 | Incyte Corp | CRYSTALLINE FORMS OF A FGFR INHIBITOR AND PROCESSES FOR ITS PREPARATION |
| HRP20230400T1 (en) | 2017-12-21 | 2023-06-23 | Boehringer Ingelheim International Gmbh | Benzylamino substituted pyridopyrimidinones and derivatives as sos1 inhibitors |
| AU2019262579B2 (en) | 2018-05-04 | 2024-09-12 | Incyte Corporation | Salts of an FGFR inhibitor |
| HRP20241288T1 (en) | 2018-05-04 | 2024-12-06 | Incyte Corporation | Solid forms of an fgfr inhibitor and processes for preparing the same |
| US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
| EA202192575A1 (en) | 2019-03-21 | 2022-01-14 | Онксео | DBAIT COMPOUNDS IN COMBINATION WITH KINASE INHIBITORS FOR CANCER TREATMENT |
| EP3986408A1 (en) | 2019-06-19 | 2022-04-27 | Boehringer Ingelheim International GmbH | Anticancer combination therapy |
| US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| BR112022001678A2 (en) * | 2019-07-30 | 2022-05-03 | Edvince Ab | Mek inhibitor, use of a mek inhibitor, method of treating or reducing the risk of developing a stroke in a subject, composition, and kit of parts |
| EP3797899A1 (en) | 2019-09-27 | 2021-03-31 | Primetals Technologies Austria GmbH | Device and method for detecting a movement of a body in an industrial installation |
| WO2021067374A1 (en) | 2019-10-01 | 2021-04-08 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| CA3157361A1 (en) | 2019-10-14 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| WO2021076728A1 (en) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| CN114761006A (en) | 2019-11-08 | 2022-07-15 | Inserm(法国国家健康医学研究院) | Methods of treating cancer resistant to kinase inhibitors |
| JP7832891B2 (en) | 2019-12-04 | 2026-03-18 | インサイト・コーポレイション | Derivatives of FGFR inhibitors |
| CA3163875A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| US12012409B2 (en) | 2020-01-15 | 2024-06-18 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| JP7808058B2 (en) * | 2020-06-02 | 2026-01-28 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Cyclofused 2-amino-3-cyanothiophenes and derivatives for treating cancer - Patents.com |
| TWI825637B (en) * | 2021-03-31 | 2023-12-11 | 美商輝瑞股份有限公司 | 3,4-dihydro-2,7-naphthyridine-1,6(2h,7h)-diones as mek inhibitors |
| JP2024514127A (en) | 2021-04-09 | 2024-03-28 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Anticancer drug therapy |
| WO2022221170A1 (en) | 2021-04-12 | 2022-10-20 | Incyte Corporation | Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent |
| WO2022221866A1 (en) * | 2021-04-16 | 2022-10-20 | Ikena Oncology, Inc. | Mek inhibitors and uses thereof |
| US12280055B2 (en) | 2021-05-27 | 2025-04-22 | Mirati Therapeutics, Inc. | Combination therapies |
| US11939331B2 (en) | 2021-06-09 | 2024-03-26 | Incyte Corporation | Tricyclic heterocycles as FGFR inhibitors |
| CA3220155A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| WO2023099608A1 (en) | 2021-12-01 | 2023-06-08 | Boehringer Ingelheim International Gmbh | Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer |
| JP2024542692A (en) | 2021-12-01 | 2024-11-15 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | KRA decomposition compounds containing cyclized 2-amino-3-cyanothiophenes |
| WO2023099624A1 (en) | 2021-12-01 | 2023-06-08 | Boehringer Ingelheim International Gmbh | Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer |
| TW202340208A (en) | 2021-12-01 | 2023-10-16 | 德商百靈佳殷格翰國際股份有限公司 | Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer |
| JP2024543976A (en) | 2021-12-01 | 2024-11-26 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Cyclized 2-amino-3-cyanothiophenes and derivatives for the treatment of cancer - Patents.com |
| CN114605408B (en) * | 2022-03-30 | 2023-06-16 | 沈阳药科大学 | 5-hydroxy-1, 3-disubstituted phenylpyrido [2,3-d ] pyrimidine compound and preparation method and application thereof |
| CN114573581B (en) * | 2022-03-30 | 2023-09-01 | 沈阳药科大学 | 5-substituted amino-1, 3-disubstituted phenylpyrido [2,3-d ] pyrimidine compound and preparation and application thereof |
| CN114456166B (en) * | 2022-03-30 | 2023-06-16 | 沈阳药科大学 | 5-substituted amino-3-methylpyrido [2,3-d ] pyrimidine compound and preparation and application thereof |
| CN114573582B (en) * | 2022-03-30 | 2023-06-16 | 沈阳药科大学 | 1,2,3, 4-tetrahydropyrido [2,3-d ] pyrimidine compound and preparation method and application thereof |
| US11878958B2 (en) | 2022-05-25 | 2024-01-23 | Ikena Oncology, Inc. | MEK inhibitors and uses thereof |
| WO2024246099A1 (en) | 2023-05-30 | 2024-12-05 | Boehringer Ingelheim International Gmbh | Spirocyclic annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer |
| WO2025073765A1 (en) | 2023-10-03 | 2025-04-10 | Institut National de la Santé et de la Recherche Médicale | Methods of prognosis and treatment of patients suffering from melanoma |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| UA72612C2 (en) * | 2000-07-06 | 2005-03-15 | Pyrido[2.3-d]pyrimidine and pyrimido[4.5-d]pyrimidine nucleoside analogues, prodrugs and method for inhibiting growth of neoplastic cells | |
| US6825180B2 (en) * | 2001-05-18 | 2004-11-30 | Cell Therapeutics, Inc. | Pyridopyrimidine compounds and their uses |
| GB0129099D0 (en) | 2001-12-05 | 2002-01-23 | Astrazeneca Ab | Chemical compounds |
| MXPA04005939A (en) * | 2002-01-22 | 2005-01-25 | Warner Lambert Co | 2-(PYRIDIN-2-YLAMINO)-PYRIDO[2,3d]PYRIMIDIN-7-ONES. |
| US7235537B2 (en) | 2002-03-13 | 2007-06-26 | Array Biopharma, Inc. | N3 alkylated benzimidazole derivatives as MEK inhibitors |
| CN1905873A (en) | 2003-11-19 | 2007-01-31 | 阵列生物制药公司 | Heterocyclic inhibitors of MEK and methods of use thereof |
| US7378423B2 (en) | 2004-06-11 | 2008-05-27 | Japan Tobacco Inc. | Pyrimidine compound and medical use thereof |
| SI1761528T1 (en) * | 2004-06-11 | 2008-06-30 | Japan Tobacco Inc | 5-AMINO-2,4,7-TRIOXO-3,4,7,8-TETRAHYDRO-2H-PYRIDO?á2,3-D?åPYRIMIDINE DERIVATIVES AND RELATED COMPOUNDS FOR THE TREATMENT OF CANCER |
| CA2761108A1 (en) | 2009-04-21 | 2010-10-28 | Novartis Ag | Heterocyclic compounds as mek inhibitors |
| NZ629432A (en) * | 2012-03-14 | 2017-01-27 | Lupin Ltd | Heterocyclyl compounds as mek inhibitors |
-
2013
- 2013-03-11 NZ NZ629432A patent/NZ629432A/en unknown
- 2013-03-11 AP AP2014008009A patent/AP3859A/en active
- 2013-03-11 ES ES13711973T patent/ES2741896T3/en active Active
- 2013-03-11 WO PCT/IB2013/051915 patent/WO2013136254A1/en not_active Ceased
- 2013-03-11 UA UAA201411014A patent/UA114907C2/en unknown
- 2013-03-11 MX MX2014010928A patent/MX355474B/en active IP Right Grant
- 2013-03-11 MX MX2018003665A patent/MX366426B/en unknown
- 2013-03-11 EA EA201491671A patent/EA029768B1/en unknown
- 2013-03-11 MX MX2014010925A patent/MX355526B/en active IP Right Grant
- 2013-03-11 AP AP2014008008A patent/AP3834A/en active
- 2013-03-11 MA MA37405A patent/MA37405A1/en unknown
- 2013-03-11 NZ NZ629442A patent/NZ629442A/en not_active IP Right Cessation
- 2013-03-11 PL PL13712929T patent/PL2834237T3/en unknown
- 2013-03-11 PE PE2014001400A patent/PE20141974A1/en active IP Right Grant
- 2013-03-11 KR KR1020197024543A patent/KR102241111B1/en active Active
- 2013-03-11 IN IN1754MUN2014 patent/IN2014MN01754A/en unknown
- 2013-03-11 CU CUP2014000109A patent/CU24335B1/en unknown
- 2013-03-11 SG SG11201405006PA patent/SG11201405006PA/en unknown
- 2013-03-11 CA CA2865167A patent/CA2865167C/en not_active Expired - Fee Related
- 2013-03-11 CN CN201810086896.8A patent/CN108383836B/en active Active
- 2013-03-11 WO PCT/IB2013/051908 patent/WO2013136249A1/en not_active Ceased
- 2013-03-11 AU AU2013234009A patent/AU2013234009B2/en active Active
- 2013-03-11 KR KR1020147028556A patent/KR20140138910A/en not_active Ceased
- 2013-03-11 EP EP13711973.1A patent/EP2834236B1/en active Active
- 2013-03-11 US US14/385,092 patent/US9428499B2/en active Active
- 2013-03-11 DK DK13711973.1T patent/DK2834236T3/en active
- 2013-03-11 TR TR2018/11976T patent/TR201811976T4/en unknown
- 2013-03-11 CN CN201380023296.2A patent/CN104271577A/en active Pending
- 2013-03-11 JP JP2014561567A patent/JP6093384B2/en active Active
- 2013-03-11 CA CA2865164A patent/CA2865164C/en active Active
- 2013-03-11 KR KR1020197017334A patent/KR102240101B1/en not_active Expired - Fee Related
- 2013-03-11 CU CUP2014000110A patent/CU24272B1/en unknown
- 2013-03-11 KR KR1020147028557A patent/KR20140138911A/en not_active Ceased
- 2013-03-11 CN CN201710823363.9A patent/CN107698585A/en active Pending
- 2013-03-11 GE GEAP201313596A patent/GEP201706774B/en unknown
- 2013-03-11 GE GEAP201313595A patent/GEP201706671B/en unknown
- 2013-03-11 PE PE2014001399A patent/PE20141973A1/en active IP Right Grant
- 2013-03-11 SG SG11201405007QA patent/SG11201405007QA/en unknown
- 2013-03-11 CN CN201380014210.XA patent/CN104203947A/en active Pending
- 2013-03-11 MY MYPI2014002639A patent/MY174188A/en unknown
- 2013-03-11 IN IN1755MUN2014 patent/IN2014MN01755A/en unknown
- 2013-03-11 JP JP2014561564A patent/JP6431770B2/en active Active
- 2013-03-11 ES ES13712929T patent/ES2684517T3/en active Active
- 2013-03-11 EP EP13712929.2A patent/EP2834237B1/en active Active
- 2013-03-11 US US14/385,106 patent/US9573944B2/en active Active
- 2013-03-11 MA MA37400A patent/MA37400B1/en unknown
- 2013-03-11 EA EA201491672A patent/EA028232B1/en unknown
- 2013-03-11 AU AU2013234014A patent/AU2013234014B2/en not_active Ceased
- 2013-03-11 BR BR112014022713-6A patent/BR112014022713B1/en active IP Right Grant
- 2013-03-11 MY MYPI2014002638A patent/MY175950A/en unknown
- 2013-03-11 DK DK13712929.2T patent/DK2834237T3/en active
- 2013-03-11 UA UAA201411011A patent/UA114906C2/en unknown
-
2014
- 2014-08-18 TN TNP2014000357A patent/TN2014000357A1/en unknown
- 2014-08-18 TN TNP2014000356A patent/TN2014000356A1/en unknown
- 2014-08-22 ZA ZA2014/06186A patent/ZA201406186B/en unknown
- 2014-09-09 IL IL234559A patent/IL234559A/en active IP Right Grant
- 2014-09-09 IL IL234560A patent/IL234560A/en active IP Right Grant
- 2014-09-10 DO DO2014000204A patent/DOP2014000204A/en unknown
- 2014-09-10 DO DO2014000203A patent/DOP2014000203A/en unknown
- 2014-09-11 NI NI201400107A patent/NI201400107A/en unknown
- 2014-09-11 NI NI201400108A patent/NI201400108A/en unknown
- 2014-09-12 CL CL2014002412A patent/CL2014002412A1/en unknown
- 2014-09-12 CL CL2014002411A patent/CL2014002411A1/en unknown
- 2014-09-12 PH PH12014502040A patent/PH12014502040B1/en unknown
- 2014-09-12 PH PH12014502041A patent/PH12014502041B1/en unknown
- 2014-09-12 GT GT201400195A patent/GT201400195A/en unknown
- 2014-09-12 GT GT201400196A patent/GT201400196A/en unknown
- 2014-10-06 CR CR20140464A patent/CR20140464A/en unknown
- 2014-10-06 CO CO14221195A patent/CO7160029A2/en unknown
- 2014-10-06 CR CR20140463A patent/CR20140463A/en unknown
- 2014-10-06 CO CO14221191A patent/CO7170131A2/en unknown
-
2016
- 2016-07-25 US US15/218,980 patent/US9555035B2/en active Active
- 2016-12-22 US US15/388,327 patent/US9969731B2/en active Active
-
2017
- 2017-01-06 US US15/400,627 patent/US9827247B2/en active Active
- 2017-01-25 AU AU2017200493A patent/AU2017200493B2/en active Active
-
2018
- 2018-04-12 AU AU2018202568A patent/AU2018202568B2/en active Active
- 2018-05-01 JP JP2018088389A patent/JP6630771B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014MN01755A (en) | ||
| MX360634B (en) | Substituted 3-haloallylamine inhibitors of ssao and uses thereof. | |
| EA201201680A1 (en) | MORFOLINOPYRIMIDINES AND THEIR APPLICATION IN THERAPY | |
| IN2014MN02598A (en) | ||
| IN2014DN09434A (en) | ||
| WO2014028600A3 (en) | 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | |
| EA201590453A1 (en) | CONDENSED BICYCLIC DERIVATIVES OF SULFAMOIL AND THEIR APPLICATION AS A MEDICINE PREPARATION FOR THE TREATMENT OF HEPATITIS B | |
| NZ721175A (en) | Syk inhibitors | |
| NZ739760A (en) | Neuroactive 19-alkoxy-17-substituted steroids, prodrugs thereof, and methods of treatment using same | |
| PH12014502524A1 (en) | Carboxylic acid compounds | |
| IN2015DN01119A (en) | ||
| EA201591195A1 (en) | NEW QUINOLON DERIVATIVES | |
| EA201390984A1 (en) | HETEROCYCLIC COMPOUNDS SUITABLE FOR THE TREATMENT OF DYSLIPIDEMIA | |
| EA201600434A1 (en) | APPLICATION OF DERIVATIVES OF BENZIMIDAZOLPROLINE | |
| EA201590183A1 (en) | AZAINDOL DERIVATIVES PERFORMING AS PI3K INHIBITORS | |
| MX2016003522A (en) | Quinazoline derivatives and their use as dna methyltransferase inhibitors. | |
| WO2012135615A3 (en) | Enopeptins, uses thereof, and methods of synthesis thereto | |
| IN2013DN02555A (en) | ||
| IN2015DN01329A (en) | ||
| UA111851C2 (en) | PIRIDASINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS |